Development and Commercialization of Next Generation of Neural Microelectrode Arr

下一代神经微电极Arr的开发和商业化

基本信息

批准号：
8250324
负责人：
Rajmohan Bhandari
金额：
$ 26.74万
依托单位：
BLACKROCK MICROSYSTEMS
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-04-01 至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8250324
关键词：
Acute Animals Architecture Biocompatible Coated Materials Characteristics Charge Chronic Clinical Research Communities Coupling Deposition Development Electrodes Engineering Film Goals Housing Human Human Resources Injection of therapeutic agent Instruction Iridium Laboratories Lead Length Maintenance Marketing Masks Metals Methodology Microelectrodes Neurons Neurosciences Neurosciences Research Partner in relationship Platinum Procedures Process Resources Scheme Scientist Shapes Site Surface System Techniques Technology Time Tissues Universities Utah Work Writing base clinical application commercialization cost density design improved interest iridium oxide manufacturing process meetings microsystems new technology next generation parylene C public health relevance relating to nervous system silicon carbide technology development

项目摘要

DESCRIPTION (provided by applicant): The array technology developed by Normann et.al. two decades ago at the University of Utah is currently being manufactured and marketed to the neuroscience research community by Blackrock Microsystems (formerly known as Cyberkinetics, Inc., CKI). The Utah electrode array (UEA) is the only high- electrode density, penetrating microelectrode array that is FDA and CE approved, for human use. These arrays, both chronic and acute, have been shown to work very well in animal subjects and their commercial availability has met with considerable interest. The 'manufacturing' procedures that are used to fabricate the UEA at present are closely based on those that were used in their initial development in the laboratory, two decades ago. To date the fabrication of the UEA's has been carried out on a single array basis and as a result the manufacturing technique is not only time consuming but also labor intensive. Also, the existing fabrication costs including utilities, manpower, and maintenance are high. More importantly, the current processes used to fabricate the UEAs impose limitations in the tolerances of the electrode array geometry and electrical characteristics. Furthermore, the flat architecture of the UEA and convoluted geometry of the targeted tissue can result in poor coupling between the two "mating" surfaces, leading to active electrode tips that are not in proximity to the target neuronal tissue. Thus for an efficient neural interface and for wide experimental usage both in experimental and clinical applications, the existing UEA fabrication technique provides inadequate quality, repeatability, and throughput. There is a need to develop less costly but higher precision batch fabrication technology. In 2006, the University of Utah proposed and began work on optimizing existing processes, exploring new materials, designing new architecture of electrode array that are compliant with the host-tissue, and last but not the least developing wafer-scale based process flow for the UEA fabrication. The applicants of this application compose of such a team of engineers, scientists that have been working together over the past years on the technology development for the UEA. The goals of this application is to transfer the manufacturing technology developed at the University of Utah to Blackrock Microsystems, making the technology into a turnkey technology that can be disseminated to the neuroscience and clinical research community, by making the existing microelectrode arrays affordable, better, reliable, and customizable for both acute and chronic applications. PUBLIC HEALTH RELEVANCE: Relevance The new technology would allow us to fabricate neural multielectrode arrays with (a) uniformly shaped microelectrodes (b) small and uniformly exposed active tip sites (c) coated with an electrode material that can deliver high charge densities i.e. high charge injection capacity (CIC) (d) deposited with a highly robust encapsulation material for chronic applications and (e) convoluted electrode arrays for better geometrical match with the targeted tissue. Furthermore the technology would provide better quality, repeatability, and higher throughput of electrode arrays at lower cost of manufacturing and faster lead time. All these advantages would help in making the electrode arrays affordable and assessable to the neuroscience community.

描述（由申请人提供）：Normann等人开发的阵列技术二十年前，在犹他大学，目前正在BlackRock Microsystems（以前称为Cyberkinetics，Inc.，CKI）生产并向神经科学研究社区销售。犹他州电极阵列（UEA）是唯一获得FDA和CE批准的高电极密度，用于人类使用。这些阵列（包括慢性和急性）已被证明在动物受试者中非常有效，它们的商业可用性引起了极大的兴趣。目前用于制造UEA的“制造”程序是基于二十年前在实验室初始开发中使用的程序。迄今为止，UEA的制造已经以一个阵列进行，因此，制造技术不仅耗时，而且还耗费劳动力。同样，包括公用事业，人力和维护在内的现有制造成本很高。更重要的是，用于制造UEAS的当前过程对电极阵列几何形状和电特性的公差施加了局限性。此外，UEA的平坦结构和靶向组织的复杂几何形状会导致两个“交配”表面之间的耦合较差，从而导致活跃的电极尖端与靶神经元组织不接近。因此，对于有效的神经界面和实验和临床应用中的广泛实验用法，现有的UEA制造技术提供了质量不足，可重复性和吞吐量。有必要发展成本较低但更高的精度批处理制造技术。 2006年，犹他大学提出并开始致力于优化现有流程，探索新材料，设计符合主机组织的电极阵列的新架构，最后但不是最不开发的UEA制造的基于晶圆的基于晶圆的过程流程。该申请的申请人组成了这样的工程师团队，在过去几年中一直在UEA技术开发方面一直在合作的科学家。该应用程序的目标是将在犹他大学开发的制造技术转移到贝莱德微系统，将技术变成一项交钥匙技术，可以通过使现有的微电极阵列可负担得起，更好，更好，可靠，可用于急性和长期应用程序，从而将其传播到神经科学和临床研究社区。公共卫生相关性：相关性新技术将使我们能够使用（a）（a）均匀形状的微电极（b）均匀且均匀裸露的活动尖端站点（c）用电极材料（可提供高电荷密度的高电荷电源（CIC）（cic）（d）涂层的电极材料（CIC）（d）材料（d）均匀暴露的活动（c）（c），高电荷（cic）（d）（c）与靶组织的几何匹配。此外，该技术将以较低的制造成本和更快的交货时间提供更好的质量，可重复性和更高的电极阵列吞吐量。所有这些优势将有助于使电极阵列负担得起，并可以对神经科学社区进行评估。